Schrödinger, Inc. is a global science and technology company specializing in computational chemistry, artificial intelligence, and molecular simulation. Founded in 1990 and headquartered in New York City, the company operates offices across the United States, Europe, and Asia. Schrödinger develops an integrated computational platform that combines physics-based modeling with machine learning to accelerate innovation in drug discovery and materials science. Its overarching goal is to enhance human health and quality of life by delivering highly accurate in silico predictions for therapeutic and industrial material design.

Corporate Structure and Mission

Schrödinger’s mission is to accelerate scientific innovation through digital chemistry approaches in molecular and materials design. With over 900 employees and more than three decades of research and development experience, the company is a leader in computational science. Its executive and scientific leadership teams include experts in chemistry, biology, artificial intelligence, and computational physics. The company’s sustainability strategy, known as VALUE², emphasizes environmental responsibility, diversity, and ethical technology practices.

Technology Platform and Product Portfolio

The Schrödinger Platform is a modular software ecosystem integrating physics-based molecular modeling with modern machine learning techniques. It supports a wide range of applications—from small-molecule drug design and protein engineering to biomolecular modeling and advanced materials development.

Key products include:

• Maestro: A central graphical interface providing access to all modeling tools.
• LiveDesign: A cloud-based collaboration environment for design, prediction, and analysis of small and large molecules.
• FEP+ (Free Energy Perturbation): A physics-based method that predicts protein–ligand binding affinities with high accuracy.
• Glide: A high-performance molecular docking software for simulating ligand–receptor interactions.

Applications

Schrödinger’s software suite is used across multiple scientific and industrial domains:

• Life Sciences: Target identification, structure-based design, lead optimization, and formulation studies.
• Materials Science: Development of polymers, catalysts, semiconductors, and energy storage materials.
• Academia: Education and research in theoretical chemistry and molecular modeling.

By integrating experimental and computational data into a single digital framework, Schrödinger enables fully digital design–build–test–analyze cycles in research and development.

Collaborations and Research Network

Schrödinger maintains strategic collaborations with major technology and pharmaceutical companies. Notably, it partners with NVIDIA to optimize GPU-based high-performance computing for molecular simulations. Its software has been applied in drug discovery programs with companies such as AbbVie, Takeda, Galapagos, and Morphic Therapeutic, where computational insights have guided the design of clinical candidates, including TYK2 and MALT1 inhibitors.

Sustainability and Social Impact

The company integrates sustainability and ethical responsibility into its corporate policies. Efforts include LEED-compliant workspaces, reduced energy consumption, carbon footprint monitoring, and efficient use of scientific resources. Schrödinger also engages in collaborative global health programs focused on early-stage discovery for diseases such as malaria, tuberculosis, and non-hormonal contraceptives.

Vision

Through the integration of physics-based modeling and artificial intelligence, Schrödinger expands the frontiers of computational design in both modern drug discovery and materials development. Its platform accelerates decision-making by merging experimental and computational insights, thereby enhancing design precision and efficiency in the molecular sciences.